ID
11320
Descripción
Study documentation part: Screening This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Palabras clave
Versiones (1)
- 30.06.15 30.06.15 -
Subido en
30. Juni 2015
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
Descripción
Demographics
Alias
- UMLS CUI-1
- C1704791
Descripción
Date of birth
Tipo de datos
date
Alias
- UMLS CUI-1
- C0421451
Descripción
Gender at birth
Tipo de datos
text
Alias
- UMLS CUI-1
- C0079399
Descripción
Race
Tipo de datos
text
Alias
- UMLS CUI-1
- C0034510
Descripción
Other race
Tipo de datos
text
Alias
- UMLS CUI-1
- C0034510
Descripción
Ethnicity (For United states only)
Tipo de datos
text
Descripción
Informed consent
Alias
- UMLS CUI-1
- C0514044
- UMLS CUI-2
- C0805443
Descripción
Was informed consent obtained prior to any study related procedures?
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0021430
Descripción
If you chose above the option "Yes", please enter the date subject or legally authorized representative signed informed consent.
Tipo de datos
date
Alias
- UMLS CUI-1
- C0011008
Descripción
Eligibility criteria
Alias
- UMLS CUI-1
- C0332307
- UMLS CUI-2
- C0030705
- UMLS CUI-3
- C1513905
- UMLS CUI-4
- C1516637
Descripción
Did the subject fail any eligibility criteria?
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0332307
- UMLS CUI-2
- C0030705
- UMLS CUI-3
- C1513905
- UMLS CUI-4
- C1516637
Descripción
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s)
Tipo de datos
text
Alias
- UMLS CUI-1
- C0231175
- UMLS CUI-2
- C1516637
- UMLS CUI-3
- C1512693
- UMLS CUI-4
- C0680251
Descripción
Pre-randomization status
Alias
- UMLS CUI-1
- C0034656
- UMLS CUI-2
- C0449438
Descripción
Will the subject be randomized?
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0034656
Descripción
If you chose "No" above, please indicate primary reason for not being randomized?
Tipo de datos
text
Alias
- UMLS CUI-1
- C0034656
Descripción
Please specify if you chose "Subject withdrew consent", "Poor/ Non-Compliance", "Subject no longer meets study criteria" or "Other"
Tipo de datos
text
Alias
- UMLS CUI-1
- C0392360
Descripción
Please specify the date of last contact, if you chose "Lost to follow-up".
Tipo de datos
date
Alias
- UMLS CUI-1
- C0011008
Descripción
Treatment assignment
Alias
- UMLS CUI-1
- C1522541
Similar models
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
C0545082 (UMLS CUI-2)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
C1516637 (UMLS CUI-2)
C1512693 (UMLS CUI-3)
C0680251 (UMLS CUI-4)
C0449438 (UMLS CUI-2)
C0027365 (UMLS CUI-2)